Amryt Pharma PLC's (LON:AMYT) Dr Joe Wiley tells Proactive London's Andrew Scott the business is well capitalised and resilient.
Pro forma revenues of the newly enlarged group were up 13.1% at US$154.1mln in the year just gone as it reported that a strong end to 2019 carried on into 2020.